Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single-Blind, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine ± OMV When Administered at an 0-2-6-Month Schedule in Healthy Adolescents 11-18 Years of Age

NCT00297817 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT00297817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00297817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single-Blind, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine ± OMV When Administered at an 0-2-6-Month Schedule in Healthy Adolescents 11-18 Years of Age
Lead sponsor
Novartis Vaccines
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
April 30, 2007
Enrollment
203 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease